| Title |
Novel Treatments in Lupus
|
|---|---|
| Published in |
Current Rheumatology Reports, March 2017
|
| DOI | 10.1007/s11926-017-0638-8 |
| Pubmed ID | |
| Authors |
Vasileios C. Kyttaris |
| Abstract |
The treatment of systemic lupus erythematosus (SLE) still depends on non-specific immunosuppression. Herein, we review promising targeted therapies that have the potential to change this therapeutic paradigm. Besides the FDA-approved B lymphocyte stimulator (BLyS) inhibitor, belimumab, interferon-α represents a promising treatment target, albeit with modest effectiveness primarily in non-renal SLE. Preclinical and early-phase clinical trials using biologics and small molecules targeting B and T cell activation as well as the cross-talk between these cells also show promise. BLyS and interferon targeting show the most promising results in challenging the current treatment status in non-renal SLE. |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 3 | 12% |
| Student > Bachelor | 3 | 12% |
| Student > Postgraduate | 3 | 12% |
| Researcher | 3 | 12% |
| Student > Doctoral Student | 2 | 8% |
| Other | 6 | 23% |
| Unknown | 6 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 46% |
| Agricultural and Biological Sciences | 3 | 12% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Unspecified | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 7 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 March 2017.
All research outputs
#20,408,464
of 22,958,253 outputs
Outputs from Current Rheumatology Reports
#647
of 718 outputs
Outputs of similar age
#271,412
of 311,212 outputs
Outputs of similar age from Current Rheumatology Reports
#20
of 24 outputs
Altmetric has tracked 22,958,253 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 718 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,212 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.